The FDA granted full approval to Alzheimer's drug Leqembi, allowing Medicare enrollees to get fully covered treatment with the drug if they qualify and agree to report data to a registry
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.
https://www.wsj.com/articles/fda-approves-leqembi-extending-alzheimers-treatment-to-more-patients-88339173July 6, 2023 4:50 pm ETBiogen developed the drug with Eisai, which said Leqembi could generate $7 billion in annual sales globally by 2030.is on its way to many more patients across the U.S.Continue reading your article with
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverageLeqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
続きを読む »
FDA Approves First Leadless Dual-Chamber Pacing SystemThe FDA has approved 'the world's first' leadless dual-chamber pacing system, one based in part on an already-approved leadless single-chamber device. MedicalNews CardioTwitter
続きを読む »
Dissolving electronic device to monitor and treat heart dysfunction gets FDA approvalNew gadget can map electrical activity and deliver electrical stimuli to stop atrial fibrillation, before dissolving into the body.
続きを読む »
New Bill Would Require Medicare to Cover 'Home Resiliency' Amid Worsening Climate Crisis“Climate justice is a matter of disability justice,' said Sen. Ed Markey. 'It's time that we guarantee that seniors and people with disabilities can safely weather the climate crisis.'
続きを読む »
Op-ed: Medicare agency limiting access to Alzheimer’s treatmentCommentary: A new treatment for Alzheimer’s disease, lecanemab, will likely receive traditional FDA approval on Thursday. Unfortunately, the Centers for Medicare & Medicaid Services is closing the door to ready access to this new treatment.
続きを読む »